Knowledgent and Talend Unveil New Customer-360 Data Management Solution
Kartridge MDM 360 Helps Healthcare, Life Sciences, Finanancial Services and Other Industries Increase Service Levels by Having a More Complete View of Each Customer
"The combination of Knowledgent's industry expertise with Talend's data integration and MDM capabilities on top of Amazon Web Services' cloud storage and database platforms, is a powerful solution for delivering an end-to-end view of patients and research," said Rolf Heimes, senior director, Global Technology Alliances. "We're excited to partner with Knowledgent on bringing this solution to market that promises to help healthcare and life sciences companies more effectively analyze data for better business and patient outcomes."
According to recent Harvard Business Review article, more than 47 percent of data has serious integrity issues causing business analysts to spend 80 percent of their time on searching for and preparing data. Kartridge MDM 360 includes visualization tools that help interpret data hierarchies and contact relationships. This provides a central point of control for data governance and stewardship functions, which helps improve data quality and compliance. Once data quality, curation and governance functions are consolidated, Kartridge MDMD 360 then combines that data with analytical engines and self-service capabilities to contextualize it in a role-based, business employee way. By combining predefined data models, data quality and self-service data discovery, Kartridge MDM 360 empowers data consumers with the information they need, while delivering a trusted 360-degree view of the enterprise. Utilizing AWS S3, Aurora, and Neptune databases, Kartridge MDM 360 can quickly incorporate multiple data resources and scale to support multi-divisional enterprise needs.
"Healthcare and life sciences organizations need effective ways to transform exploding volumes of diverse real-world data into real-world evidence they can leverage with analytics, cognitive computing and the cloud to deliver unprecedented patient value," said Chris Blotto, CIO, Knowledgent. "Kartridge MDM 360 provides an easy-to-deploy, budget-friendly solution for highly regulated healthcare and life sciences organizations, as well as of other industries with customer-centric data needs."
Using Kartridge MDM 360, healthcare and life sciences users can easily locate, combine, cleanse, qualify, and analyze data from a diverse array of sources including EHR and insurance claims systems, clinical trials, patient monitoring devices, smartphones, and social media. Potential use cases for Kartridge MDM 360 include:
- Clinical trial innovation
- Fraud, waste, and abuse analysis
- Scientific search
- Treatment adherence
- Patient recruitment
- Drug responsiveness
- Adverse event processing automation
- Next best action
- Regulatory intelligence
For more information on Knowledgent's Kartridge MDM 360 visit https://knowledgent.com/kartridgemdm360/ or register here to view the live-streamed keynote presentation by Chris Blotto, CTO for Knowledgent, on Wednesday, May 9 at 9:45 am ET. Additional information on Talend and its complete portfolio of offerings can be found at www.talend.com.
Like this Story? Tweet this: #Talend and Knowledgent unveil KartridgeMDM360 to help organizations optimize the information supply chain #TalendConnect
Siobhan Lyons Talend 2024319411 email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Talend via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
SDRL – Seadrill Limited Announces Contract Award for the West Gemini17.7.2019 22:35:00 CEST | Press release
Hamilton, Bermuda, July 17, 2019 - Seadrill Limited ("Seadrill" or "the Company") has secured a nine well contract with three options, each for two wells, for the West Gemini in West Africa. Total contract value for the firm portion of the contract is expected to be approximately $84 million with commencement expected in early Q4 2019 and running through Q4 2020. FORWARD LOOKING STATEMENTS This news release includes forward looking statements. Such statements are generally not historical in nature, and specifically include statements about the Company's plans, strategies, business prospects, changes and trends in its business, the markets in which it operates and its restructuring efforts. These statements are made based upon management's current plans, expectations, assumptions and beliefs concerning future events impacting the Company and therefore involve a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or imp
GrandVision confirms HAL and EssilorLuxotica are engaged in discussions on a possible sale of controlling interest of HAL in GrandVision17.7.2019 18:45:00 CEST | Press release
Schiphol, The Netherlands - 17 July 2019. GrandVision NV (Euronext: GVNV) confirms that it has been approached by EssilorLuxottica SA (Euronext: EL) and HAL Holding NV (Euronext: HAL) in connection with a possible sale of HAL’s 76.72% ownership interest in GrandVision to EssilorLuxottica at an envisaged purchase price per share of approximately EUR28.00. At this stage it is uncertain whether an agreement between EssilorLuxottica and HAL will be reached. While a transaction would be between HAL and EssilorLuxottica, GrandVision’s support has been requested. Completion of a sale of HAL’s ownership interest in GrandVision would be subject to customary conditions including approval from relevant regulatory authorities in various jurisdictions, which may take between 12 and 24 months. Following completion of the transaction between HAL and EssilorLuxottica, EssilorLuxottica will make a (mandatory) public offer for all shares in GrandVision. Further announcements will be made if and when req
Solutions 30 : 79.8% revenue growth in the first half of 201917.7.2019 18:00:00 CEST | Press release
79.8% revenue growth in the first half of 2019 France: revenue up 74.4% Other countries: revenue up 90.3% Reliable, cash-generating model Solutions 30 SE, the European leader in solutions for new technologies, today disclosed its revenue for the first half of 2019 . In millions of euros (Unaudited figures) HY Q2 2019 2018 % change 2019 2018 % change Total 317.8 176.7 +79.8% 157.4 91.5 +72.1% From France 202.8 116.3 +74.4% 101.5 59.5 +70.6% From other countries 115.0 60.4 +90.3% 55.9 32.0 +74.7% Sustained growth trend continues Solutions 30 maintains its high growth trajectory, disclosing revenues of €317.8 million for the first half of 2019, a 79.8% increase (36.9% of which was organic growth1). For the 2nd quarter alone, revenue increased by 72.1%, reaching €157.4 million. Organic growth represented 32.3%. The group continues to demonstrate the relevance of its positioning and strategy in markets driven by the economy’s digital transformation and major technology groups’ outsourcing o
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban17.7.2019 18:00:00 CEST | Press release
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA - July 17, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today hosted a key opinion leader (KOL) meeting in New York City on in-vitro fertilization (IVF). At the event, three KOLs in women’s reproductive health along with company executives discussed trends in IVF, including current practice trends toward Day 5 embryo transfer, and the merits of single-embryo transfer (SET) vs. double embryo transfer (DET). Further, event participants discussed the potential clinical importance of nolasiban, ObsEva’s oral oxytocin receptor antagonist, to significantly improve the live birth rate (LBR) resulting from ET, and address the high physical, emotional and financial pain associated with fa
Bizagi goes from Stealth to Hyper Growth Delivering Digital Transformation for World Leading Brands17.7.2019 18:00:00 CEST | Press release
From Adidas and Audi to Ikea and the U.S. government, Bizagi’s unique Intelligent Process Automation helping organizations harness the power of RPA and AI to speed transformation SANTA CLARA, Calif., July 17, 2019 (GLOBE NEWSWIRE) -- Bizagi, the world’s leading Intelligent Process Automation platform provider, today announced significant growth in the U.S. and abroad driven by its success enabling digital transformation for world leading brands such as DHL, Gap, Citizens Bank, AON and numerous U.S. government agencies including the Departments of Agriculture, Defense, Energy, HHS, Homeland Security and many others. Bizagi’s growth is based on enterprise adoption of its unique Intelligent Process Automation, enabling companies to better leverage digital and robotic processes, along with artificial intelligence, to improve customer interaction, speed operations and build revenue. This news follows the company’s recognition last month as a leader in The Forrester Wave™: Software for Digit
EnBW International Finance B.V.: Half-yearly report17.7.2019 17:00:00 CEST | Press release
EnBW International Finance B.V.: Half-yearly report 2019 In accordance with the Transparency Directive (Directive 2004/109/EC), as amended by the Transparency Directive Amending Directive (Directive 2013/50/EU), and following the choice of EnBW International Finance B.V. for The Netherlands as Home Member State, EnBW International Finance B.V. hereby informs that the half-year financial reports for the period 1 January 2019 till 30 June 2019 have been filed on 17 July 2019 with the Autoriteit Financiële Markten (AFM) in The Netherlands and are available on the internet site: https://www.enbw.com/unternehmen/investoren/news-und-publikationen/publikationen/